Shanghai Junshi Biosciences (HKG:1877, SHA:688180) obtained approval from Australia's Therapeutic Goods Administration (TGA) to market the drug toripalimab, according to a Hong Kong Stock Exchange disclosure on Jan. 17.
The TGA approved the new chemical entity application for toripalimab in combination with cisplatin and gemcitabine as a treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma or NPC.
Toripalimab was also approved as a single agent to treat adults with unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy, the filing said.
The pharmaceutical company's Shanghai shares rose more than 1% and Hong Kong shares climbed less than 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。